Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Trading 1.2% Higher

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) shares traded up 1.2% during mid-day trading on Monday . The company traded as high as $39.25 and last traded at $39.25. 784 shares traded hands during trading, a decline of 92% from the average session volume of 10,242 shares. The stock had previously closed at $38.78.

Wall Street Analyst Weigh In

CALT has been the topic of several research analyst reports. Citigroup reiterated a “neutral” rating and issued a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a research note on Friday, May 31st. Jefferies Financial Group restated a “hold” rating and issued a $39.00 target price (down previously from $58.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. Lifesci Capital lowered shares of Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 28th. HC Wainwright reiterated a “neutral” rating and issued a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $40.00 price objective (down previously from $55.00) on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday, May 28th. Six equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, Calliditas Therapeutics AB (publ) presently has an average rating of “Hold” and a consensus target price of $35.00.

Calliditas Therapeutics AB (publ) Stock Performance

The company has a market cap of $1.18 billion, a PE ratio of -21.05 and a beta of 1.77. The firm’s 50 day moving average is $38.98 and its 200-day moving average is $27.53. The company has a debt-to-equity ratio of 8.46, a quick ratio of 2.62 and a current ratio of 2.69.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last announced its quarterly earnings results on Thursday, May 23rd. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.74). Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 160.87%. The business had revenue of $28.43 million during the quarter, compared to analyst estimates of $35.78 million. On average, research analysts anticipate that Calliditas Therapeutics AB will post -0.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

An institutional investor recently bought a new position in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new stake in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors and hedge funds own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.